Your Health/tech start-up has evidence. Now it’s time to build demand.

Your clinical evidence is solid. Your pilot worked. Clinicians like the product.

Maybe you even have regulatory clearance, peer-reviewed data and a respected medical advisor on the deck.

And yet, the contracts are not coming.

Sales cycles drag. Pilots don't convert. Procurement goes quiet. Another hospital tells you they are “interested”, but not quite ready.

For health/tech scale-ups across APAC, this is one of the most frustrating stages of growth:

You have proved the technology works. But you haven't proved why the health system should buy it.

Executive Summary

Clinical evidence can get your health/tech taken seriously. It does not automatically get it bought.

Healthcare buyers increasingly need evidence of clinical value, economic value and implementation value.

The companies that understand this stop selling the technology... and start making the case for adoption.

Health/tech companies are told constantly to “build the evidence.”

So they do.

They validate accuracy. Run studies. Publish outcomes. Secure regulatory approvals. Recruit KOLs.

Then commercial teams take that evidence into the market expecting it to shorten the sales cycle.

Except healthcare systems aren't simply asking: “Does this work?”

They are also asking: “Can we actually make this work here?”

That distinction matters.

WHO describes Health Technology Assessment as evaluating not only clinical consequences, but also economic, ethical and social implications.

Its 2025 guidance on medical devices explicitly positions HTA as a mechanism for informing adoption and reimbursement decisions.

In other words: Evidence of efficacy is not the same as evidence of value.

And evidence of value is not necessarily evidence that your solution can survive contact with a real healthcare system.

Look at where Singapore is heading

Singapore provides a useful signal for the wider APAC health/tech market. The country isn't backing away from healthcare innovation. Quite the opposite.

In May 2026, Singapore's Ministry of Health announced S$2.5 billion over five years under the RIE2030 plan to strengthen translational and clinical research.

But look carefully at the language surrounding that investment.

For precision medicine, the ambition is to generate local evidence demonstrating how genomics can be integrated into healthcare responsibly and effectively, in both clinical and economic terms.

For AI, the emphasis includes integration into regular clinical workflows, alongside validation and explainability so clinicians and patients can have confidence in the technology.

That is the commercial signal health/tech founders should pay attention to.

The bar isn't: “Show me your AI works.”

It is increasingly: “Show me where it fits, who benefits, what changes, what it costs and why adopting it is worth the disruption.”

Singapore's Health Minister made the point even more explicitly in July: healthcare AI should not become “a solution looking for problems”; adoption should begin with the use case, and effective solutions can then be scaled system-wide.

That's a buying philosophy, not just a tech philosophy.

The execution playbook

If your health/tech has evidence but commercial traction remains slow, I would pressure-test three things.

1. Move from clinical proof to buyer proof

Your study endpoint may matter enormously to a clinician. It may mean considerably less to a CFO, hospital operator or procurement team.

Different stakeholders need different proof.

• Clinical leaders may ask about safety, outcomes and reliability.

• Operations may ask whether you reduce workload or create another workflow.

• IT will care about integration, interoperability, cybersecurity and governance.

• Finance will want to understand cost, resource utilisation and measurable economic value.

• Leadership will ask whether this solves a sufficiently important organisational problem.

Same technology. Five different definitions of value.

Your commercial narrative has to translate the evidence accordingly.

2. Sell the workflow, not the feature

One of the biggest mistakes in health/tech marketing is treating superior technology as the product.

It isn't.

The NEW WORKFLOW is the product.

WHO's 2025 work on digital-health adoption highlights barriers including infrastructure, training, time, workload, legal, ethical and technical factors. Its Western Pacific framework similarly puts governance, infrastructure, financing, solutions and data at the centre of digital-health implementation.

So don't just demonstrate what happens when someone clicks the button.

Show:

Before: what happens today?

During: where does your solution enter the workflow?

After: what becomes faster, cheaper, safer or easier?

At scale: what has to change for 10 clinicians to become 1,000?

The less imagination you require from the buyer, the easier your technology becomes to champion internally.

3. Build commercial evidence alongside clinical evidence

This is where many promising health/tech companies wait too long.

Your next pilot should not only ask: “Did patient or clinical outcomes improve?”

It should also ask:

• How much clinician or administrative time was saved?

• Did utilisation or throughput change?

• What happened to cost per patient?

• How difficult was implementation?

• How quickly did users adopt it?

• What resources were required?

• What is the economic case for scaling?

Singapore already offers a simple example of why operational proof matters.

By December 2025, SingHealth's generative-AI tool Note Buddy had generated over 67,000 notes for more than 5,000 staff across public healthcare institutions and clusters, according to MOH.

Notice the power of that story.

It's not merely “our AI can generate clinical notes.”

It's evidence of the technology operating inside healthcare at meaningful scale.

That's a much stronger commercial story.

Evidence gets you through the first door. Adoption evidence gets you through the next five.

APAC doesn't have a shortage of health/tech innovation.

It has a growing need to distinguish interesting tech from tech that healthcare systems can actually absorb, fund and scale.

So if your evidence is strong but revenue isn't following, don't immediately assume you need another study.

You may need a better translation layer between clinical proof and commercial value.

Because the question your buyer is trying to answer isn't simply: “Does it work?”

It's: “Will it work here, for us, at scale... and is changing what we already do worth it?”

Your marketing, evidence strategy and commercial narrative need to answer that question before your sales team enters the room.

If you are building a health/tech business in APAC and struggling to turn strong evidence into market adoption, message me. I am always interested in discussing where the gap sits between clinical credibility and commercial traction.

Hope you enjoy this newsletter. See you in the next one. Cheers